title: Development of antibody arrays for monoclonal antibody Higher Order Structure analysis.
abstract: Antibody arrays were developed to probe a monoclonal antibody's three-dimensional structure (3-D structure). Peptides with overlapping regions were designed to cover the whole mAb light chain and heavy chain, respectively, and used to generate polyclonal antibodies after the conjugation of the peptides to a carrier protein, KLH. It was shown that good peptide specificity was achieved from the antibodies generated. Using more than 30 different polyclonal antibodies to measure the surface epitope distribution, it was shown that the mAb antibody array can detect epitope exposure as low as 0.1% of defined mAb populations. This ELISA-based analysis of mAb epitope exposure can be considered as a measurement of "conformational impurity" in biologics development, similar to the analysis of other product-related impurities such as different forms of glycosylation, deamidation, and oxidation. This analysis of "conformational impurity" could provide valuable information on the mAb conformational comparability for biosimilar mAbs as well as novel mAbs, especially in the area of protein immunogenicity. Furthermore, stability studies indicated that there are several conformational "hot spots" in many mAbs tested, especially in the hinge region. This antibody array technology can be used for novel mAb Higher Order Structure (HOS) analysis during process and formulation development. Another important area of application is for biosimilar mAb development where the innovator molecule and biosimilar molecule could be compared based on their systemic "fingerprint" from the 30 plus antibodies.
authors: Array Bridge Inc. St. Louis, MO, USA.
authors: Xing
authors: X
authors: Wang
authors: Qing
authors: Q
authors: Li
authors: Michael
authors: M
authors: Davies
keywords: ELISA; Higher Order Structure; biosimilars; comparability; conformational stability; monoclonal antibody
references: J Am Soc Mass Spectrom. 2012 Sep;23(9):1512-21
references: 22692830
references: Annu Rev Biophys Biophys Chem. 1991;20:519-38
references: 1867725
references: Pharm Res. 2005 Dec;22(12):1997-2006
references: 16184451
references: FEBS Lett. 2011 Apr 6;585(7):995-1000
references: 21402074
references: Med Microbiol Immunol. 1992;181(4):215-26
references: 1279369
references: Mol Cell Proteomics. 2010 Aug;9(8):1716-28
references: 20103567
references: J Am Soc Mass Spectrom. 2012 Jun;23(6):1147-56
references: 22392622
references: Pharm Res. 2004 Jun;21(6):897-903
references: 15212151
references: MAbs. 2009 May-Jun;1(3):254-67
references: 20065649
references: J Am Soc Mass Spectrom. 2012 Mar;23(3):498-504
references: 22227798
references: Proc Natl Acad Sci U S A. 1981 Jan;78(1):524-8
references: 6787591
references: Pharm Res. 2009 Jun;26(6):1303-14
references: 19247815
references: Proteins. 2006 Dec 1;65(4):889-97
references: 17019719
references: Curr Med Chem. 2009;16(33):4399-418
references: 19835565
references: J Am Soc Mass Spectrom. 2012 Jun;23(6):1003-10
references: 22476891
references: J Pharm Sci. 2011 Jun;100(6):2071-86
references: 21491437
references: Science. 2003 Feb 28;299(5611):1362-7
references: 12610298
references: Nucleic Acids Res. 2009 Jul;37(Web Server issue):W498-503
references: 19433514
references: Eur J Immunol. 1991 Jun;21(6):1475-80
references: 1710568
references: Nat Biotechnol. 2009 Feb;27(2):157-67
references: 19204698
references: Proc Natl Acad Sci U S A. 1983 Feb;80(4):1137-43
references: 6573659
references: PLoS One. 2012;7(2):e31948
references: 22384109
references: Anal Chem. 2009 Apr 1;81(7):2644-51
references: 19265386